Brokerages Set Akoya Biosciences, Inc. (NASDAQ:AKYA) Target Price at $3.98

Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) have received a consensus rating of “Hold” from the six analysts that are presently covering the company, Marketbeat reports. Six analysts have rated the stock with a hold rating. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $3.98.

A number of equities research analysts recently commented on the company. Piper Sandler downgraded Akoya Biosciences from an “overweight” rating to a “neutral” rating and set a $2.40 price objective for the company. in a report on Wednesday, March 5th. Canaccord Genuity Group downgraded Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th.

Akoya Biosciences Trading Up 4.0 %

NASDAQ AKYA opened at $1.56 on Friday. The stock has a 50-day simple moving average of $2.32 and a 200 day simple moving average of $2.53. The company has a market capitalization of $77.33 million, a PE ratio of -1.32 and a beta of 1.32. The company has a current ratio of 2.75, a quick ratio of 1.85 and a debt-to-equity ratio of 5.62. Akoya Biosciences has a 12 month low of $1.43 and a 12 month high of $5.16.

Institutional Investors Weigh In On Akoya Biosciences

Several large investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new position in shares of Akoya Biosciences during the fourth quarter worth about $28,000. Barclays PLC boosted its position in shares of Akoya Biosciences by 320.9% during the third quarter. Barclays PLC now owns 39,472 shares of the company’s stock worth $107,000 after buying an additional 30,095 shares during the period. State Street Corp boosted its position in shares of Akoya Biosciences by 4.2% during the third quarter. State Street Corp now owns 453,296 shares of the company’s stock worth $1,233,000 after buying an additional 18,361 shares during the period. GSA Capital Partners LLP boosted its position in shares of Akoya Biosciences by 87.4% during the third quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock worth $845,000 after buying an additional 144,903 shares during the period. Finally, SVB Wealth LLC acquired a new position in shares of Akoya Biosciences during the fourth quarter worth about $1,180,000. 79.42% of the stock is currently owned by institutional investors.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.